SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SNY

Sanofi (NASDAQ:SNY)

FR · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - General
43.13+0.89 (+2.11%)
 
Market cap
$103B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 1, 2002
Website
Market Cap103.35B-15.3%
Revenue (ttm)48.92B+13.4%
Net Income3.96B-56.6%
EPS0.48-87.2%
Shares Out2.40B
PE Ratio23.29
Forward PE9.84
Dividend$4.17(10.94%)
Ex-Dividend DateMay 4, 2026
Volume4,264,887
Open42.34
Previous Close42.24
Day's Range42.17 - 43.14
52-Week Range39.07 - 52.68
Beta0.30
AnalystsHold
Price Target49.00(+13.61%)
Earnings DateOct 30, 2026
Insider Score
/ 99
SNY Insider Score

Sanofi has a live Insider Score.

Scored on 1 qualifying trade from 1 insider in the last 90 days.

Unlock SNY’s Insider Score

About SNY

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Address
46, avenue de la Grande ArmEe, Paris, IF, 75017, FR
Market Cap
103.35 billion
Employees
76,493
Industrial Classification
Drug Manufacturers - General

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$12.07B
Bought
$2.74B

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Sound
From SNY’s reported statements · Q2 2026 (trailing 12 months)

Next catalysts

Ask Barron about SNY

1 Day
+2.11%
5 Days
+3.43%
1 Month
+4.61%
6 Months
-7.41%
1 Year
-15.33%

$SNY stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of SNY by members of U.S. Congress

PoliticianTypeTraded
Alan ArmstrongSenate / RPurchase$15.00K – $50.00KMar 30, 2026

Recently reported changes in SNY holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SNY's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SNY Estimated quarterly lobbying spending

Source: U.S. Senate LDA

SNY Revenue by Segment or Geography

SNY's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New SNY patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SNY from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in SNY

ETFEst. Holding Size
AVDEAvantis International Equity ETF$43.97M
AFTYPacer CSOP FTSE China A50 ETF$41.22M
FENIFidelity Enhanced International ETF$38.00M
PPHVanEck Pharmaceutical ETF$34.46M
FVLFirst Trust Value Line 100 Exchange-Traded Fund$33.52M
FVDFirst Trust Value Line Dividend Index Fund$33.52M

Estimated from each fund’s disclosed top holdings × AUM

SNY Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Members only

The live Insider Score for SNY is included with Insider Access.

Unlock Insider Score

Bull Case vs Bear Case

AI-generated from SNY’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

Members only

The live Insider Score and its full factor breakdown are included with Insider Access.

Unlock Insider Score

Recent Insider Activity

Buys
6
Sells
8
Buy Value
$2.74B
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.